Robin Dulman

Clinical trials

• A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

  Site PI · Recruiting · Phase 3

  Children's Oncology Group

  2026–2031
• A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  Site PI · Recruiting · Phase 2

  National Cancer Institute (NCI)

  2025–2030
• A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

  Site PI · Recruiting · Phase 3

  Children's Oncology Group

  2025–2031
• A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

  Site PI · Recruiting · Phase 3

  National Cancer Institute (NCI)

  2023–2031